OUTLOOK THERAPEUTICS INC
NASDAQ: OTLK (Outlook Therapeutics, Inc.)
Last update: 2 hours ago1.80
0.03 (1.69%)
| Previous Close | 1.77 |
| Open | 1.77 |
| Volume | 1,884,926 |
| Avg. Volume (3M) | 571,680 |
| Market Cap | 77,136,656 |
| Price / Earnings (TTM) | 0.440 |
| Price / Sales | 13.27 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Diluted EPS (TTM) | 4.09 |
| Current Ratio (MRQ) | 0.720 |
| Operating Cash Flow (TTM) | -64.05 M |
| Levered Free Cash Flow (TTM) | -35.91 M |
| Return on Assets (TTM) | -122.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Outlook Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 1.13 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 38.31% |
| % Held by Institutions | 16.81% |
| 52 Weeks Range | ||
| Median | 21.00 (1,066.67%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Ascendiant Capital | 06 Jun 2025 | 21.00 (1,066.67%) | Buy | 1.90 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |